Bernd Kasper
A5076043217- Sarcoma Diagnosis and Treatment
- Vascular Tumors and Angiosarcomas
- Soft tissue tumor case studies
- Cardiac tumors and thrombi
- Lymphoma Diagnosis and Treatment
- Gastrointestinal Tumor Research and Treatment
- Cancer Genomics and Diagnostics
- Tumors and Oncological Cases
- Bone Tumor Diagnosis and Treatments
- CAR-T cell therapy research
- Cancer Diagnosis and Treatment
- Soft tissue tumors and treatment
- Management of metastatic bone disease
- Neurofibromatosis and Schwannoma Cases
- Colorectal and Anal Carcinomas
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Histone Deacetylase Inhibitors Research
- Medical Imaging Techniques and Applications
- Metastasis and carcinoma case studies
- Radiomics and Machine Learning in Medical Imaging
- Protein Degradation and Inhibitors
- Cancer survivorship and care
- Economic and Financial Impacts of Cancer
- Colorectal Cancer Treatments and Studies
University Hospital Heidelberg
2016-2025
Heidelberg University
2016-2025
University Medical Centre Mannheim
2016-2025
University Medical Center
2013-2023
Instituto Nacional de Enfermedades Neoplásicas
2022
University of Mannheim
2014-2021
Institute of Cancer Research
2020
European Society for Medical Oncology
2018
Eurac Research
2018
The University of Texas MD Anderson Cancer Center
2013
Soft tissue sarcomas (STSs) gather over 80 histological entities, with even more molecular subsets, characterised by a low to very incidence in all populations. The majority of arise from the soft (close 75%), ∼15% gastrointestinal stromal tumours (GISTs) and 10% bone sarcomas. These ESMO–EURACAN (European Society for Medical Oncology–European Reference Network rare adult solid cancers) Clinical Practice Guidelines cover STSs, while GISTs are covered dedicated [1.Casali P.G. Abecassis N....
Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted incidence of around 1/100 000/year [1.Nilsson B. Bümming P. Meis-Kindblom J.M. et al.Gastrointestinal tumors: the incidence, prevalence, clinical course, and prognostication in preimatinib mesylate era–a population-based study western Sweden.Cancer. 2005; 103: 821-829Crossref PubMed Scopus (1027) Google Scholar]. This only covers clinically relevant GISTs, since, if investigated, a much higher number...
Primary bone tumours are rare, accounting for < 0.2% of malignant neoplasms registered in the EUROCARE (European Cancer Registry based study on survival and care cancer patients) database [1.Stiller C.A. Trama A. Serraino D. Descriptive epidemiology sarcomas Europe: report from RARECARE project.Eur J Cancer. 2013; 49: 684-695Abstract Full Text PDF PubMed Scopus (265) Google Scholar]. Different tumour subtypes have distinct patterns incidence, each has no more than 0.3 incident cases per 100...
Leiomyosarcoma (LMS) is an aggressive mesenchymal malignancy with few therapeutic options. The mechanisms underlying LMS development, including clinically actionable genetic vulnerabilities, are largely unknown. Here we show, using whole-exome and transcriptome sequencing, that tumors characterized by substantial mutational heterogeneity, near-universal inactivation of TP53 RB1, widespread DNA copy number alterations chromothripsis, frequent whole-genome duplication. Furthermore, detect...
Background: Pazopanib is a multitargeted tyrosine kinase inhibitor approved for the treatment of patients with selective subtypes advanced soft tissue sarcoma (STS) who have previously received standard chemotherapy including anthracyclines. Data on efficacy in vascular sarcomas are limited. The main objective this study was to investigate activity pazopanib sarcomas.Patients and methods: A retrospective sarcomas, angiosarcoma (AS), epithelioid hemangioendothelioma (HE) intimal (IS) treated...
Background Among sarcomas, which are rare cancers, many types exceedingly rare; however, a definition of ultra‐rare cancers has not been established. The problem sarcomas is particularly relevant because they represent unique diseases, and their rarity poses major challenges for diagnosis, understanding disease biology, generating clinical evidence to support new drug development, achieving formal authorization novel therapies. Methods Connective Tissue Oncology Society promoted consensus...
Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue without approved treatments. Download a PDF of the Research Summary. We conducted phase 3, international, double-blind, randomized, placebo-controlled trial nirogacestat in adults with progressing desmoid according to Response Evaluation Criteria Solid Tumors, version 1.1. Patients were assigned 1:1 ratio receive oral γ-secretase inhibitor (150 mg) or placebo twice daily. The primary end point was progression-free...
The optimal treatment for advanced leiomyosarcoma is still debated. Given histotype-specific prospective controlled data lacking, this study retrospectively evaluated doxorubicin plus dacarbazine, ifosfamide, and alone as first-line treatments advanced/metastatic treated at European Organization Research Treatment of Cancer Soft Tissue Bone Sarcoma Group (EORTC-STBSG) sites.The inclusion criteria were a confirmed histological diagnosis, between January 2010 December 2015, measurable disease...
PURPOSE Doxorubicin is a standard of care in patients with advanced, inoperable soft tissue sarcoma (STS). We tested whether pazopanib has efficacy comparable to that doxorubicin elderly STS and offers superior tolerability for hematologic toxicity. PATIENTS AND METHODS Patients age 60 years or older without previous systemic treatment progressive advanced metastatic who had Eastern Cooperative Oncology Group performance status 0 2 adequate organ function were included. Treatment consisted...
The population-based incidence of sarcoma and its histological subtypes in Germany is unknown. Up-to-date information on a disease with an comparable to other cancer entities high public health relevance. aim this study was determine detect significant changes trends using data from German epidemiological registries.Pooled the Centre for Cancer Registry Data primary diagnosis occurring 2013 were used. To date, latest available Germany. All registries sufficient completeness included (10 out...